2-([5,6-二氢-7-(1H-咪唑-1-基)-2-萘基]氧基)-2-甲基丙酸乙酯作为一种具有独特特性的新型强效氧代异丁酸类降血脂药物。
Ethyl 2-([5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl]oxy)- 2-methylpropanoate as a new potent oxyisobutyrate hypolipidaemic with unusual features.
作者信息
Cozzi P, Branzoli U, Carganico G, Chiari A, Lovisolo P P, Severino D
机构信息
Chemical Research, Farmitalia Carlo ERBA S.p.A., Milano, Italy.
出版信息
Farmaco Sci. 1987 Mar;42(3):205-18.
Some compounds containing the N-imidazolyl and the ethyl oxy-isobutyrate groups linked to a naphthalene ring structure and some related analogues were synthesized and tested for hypolipidaemic activity. Ethyl 2-([5,6- dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl]oxy)- 2-methylpropanoate (V) proved to be a strong hypolipidaemic agent, several times more potent than clofibrate. Structural requirements for activity and differences from clofibrate analogues are discussed.
合成了一些含有与萘环结构相连的N - 咪唑基和乙氧基异丁酸酯基团的化合物以及一些相关类似物，并对其降血脂活性进行了测试。2 - ([5,6 - 二氢 - 7 - (1H - 咪唑 - 1 - 基)-2 - 萘基]氧基)-2 - 甲基丙酸乙酯（V）被证明是一种强效降血脂剂，其效力比氯贝丁酯强几倍。讨论了活性的结构要求以及与氯贝丁酯类似物的差异。
Zotero 插件